Header Logo

Connection

DANIEL D KARP to Dasatinib

Back to Details
This is a "connection" page, showing publications DANIEL D KARP has written about Dasatinib.
DANIEL D KARP
Connection Strength
0.112
Dasatinib
  1. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423.
    View in: PubMed
    Score: 0.112
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.